Rhythm Pharmaceuticals Inc. announced that the results of its Phase 3 Transcend clinical trial for acquired hypothalamic obesity have been published in the top international medical journal, The New England Journal of Medicine.

The publication of this paper marks the formal recognition and attention of this trial data by the authoritative medical community. The research focuses on evaluating the efficacy and safety of the company’s investigational therapy in patients with severe obesity caused by hypothalamic injury. Acquired hypothalamic obesity is a rare and serious disease, often caused by damage to the hypothalamus from brain tumors, surgery, or trauma. Patients typically face uncontrollable weight gain, severe hunger, and metabolic disorders, with very limited existing treatment options.The detailed data released in this top-tier journal lays a solid scientific foundation for subsequent communications with regulatory agencies and the advancement of potential therapies. The company hopes that this progress will bring new hope to patients suffering from this debilitating disease.